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The cumulative incidence of candidemia in an Irish Intensive Care Unit (ICU) setting 
between January 2004 and August 2018 was 17/1000 ICU admissions. Candida 
albicans was responsible for 55% (n=41). C. glabrata (n=21: 28%) was the next most 
prevalent species; identified most frequently since 2012. C. glabrata was associated 
with a higher mortality rate (57%) than C. albicans (29%). All isolates were 
susceptible to caspofungin (0.05 µg/ml). Notably, 37% of C. glabrata isolates were 
fluconazole resistant, with 13% resistant to amphotericin B, highlighting need for 
prudent antifungal stewardship to impede development of multidrug-resistant C. 




















Invasive candidiasis is a challenging complication in the intensive care unit (ICU) 
setting. A 2003 UK study reported incidence of candidemia at 7.4/1000 ICU 
admissions [1]. Predominantly nosocomial, Candida species represent the fourth 
most frequently isolated pathogens in blood stream infection (BSI) in the US [1].  
Candidemia is characterized by a high mortality rate of 36-63% [2]. Performed in the 
UK, the prospective NEMIS study of risk factors for development of candidemia in 
ICUs reported a mortality rate of 41% among patients with candidemia versus non-
candidemia patients [3]. The study listed surgery as a major risk factor, with 
abdominal procedures most associated followed by sepsis and acute renal failure. 
Parenteral nutrition and administration of antimicrobials targeting anaerobic 
pathogens were also identified as risk factors [3].  
ESCMID published guidelines in 2012 supporting clinical decisions regarding 
management of invasive candidiasis. The guidelines attempted to clarify eligibility of 
patients for prophylaxis. Specifically, prophylaxis was only recommended moderately 
in cases of recent abdominal surgery and recurrent intestinal perforations [4]. 
Traditionally, fluconazole has been considered most useful for treatment of 
candidemia [4], but introduction of echinocandins (including anidulafungin, 
caspofungin and micafungin) reduced reliance on fluconazole. This is important as 
fluconazole efficacy against non-C. albicans species including C. glabrata and C. 
krusei is unreliable [5], and increasingly a limitation in the context of increased 
prevalence of non-C. albicans species.  
Invasive candidiasis is caused typically by one of five Candida species (C. albicans, 
C. glabrata, C. tropicalis, C. parapsilosis, or C. krusei) [6]. The ARTEMIS DISK 
surveillance study compiled candidemia isolate data from 127 medical centres and 
found C. albicans to be the primary causative agent (62%) [7]. However, prevalence 
of C. albicans has decreased steadily [6], concomitant with an increase in C. 
glabrata and C. parapsilosis species. Factors determining species distribution 
include geography, antifungal therapy and patient factors [8]. In northern Europe and 
the US, increased incidence of C. glabrata has been observed, while both Spanish 
and Brazilian reports describe increased prevalence of C. parapsilosis [6]. A large 















distribution, stated that fluconazole therapy increased prevalence of fluconazole 
resistant strains of C. glabrata and C. krusei [9]. 
Such trends however have not yet been reported in Ireland. Therefore, this study 
determined whether changes in incidence of Candida species and antifungal 
susceptibility had occurred in the ICU of a large tertiary hospital, assessing records 
between January 2004 and August 2018. Our objective was to provide insight into 



















University Hospital Limerick (UHL) in Ireland’s mid-West has circa 480 inpatient beds 
for a catchment population of 400,000. At the time of writing, UHL ICU is an 8-bed 
facility with approximately 300 admissions per annum. ICU admissions are received 
from the Emergency department, other UHL departments and from five hospitals 
within the UL hospitals group.  
 
Study Design 
Analysis of data, including chart reviews, relevant to any patient in ICU with Candida-
positive blood culture between January 2004 and August 2018.  Patient 
demographics, clinical management & empirical therapy, duration of stay, presence 
of a Central Venous Catheter (CVC), outcomes, identification of Candida isolates 
and antifungal susceptibility were reviewed. The SOFA Score (sepsis-related organ 
failure assessment) was used a marker of predicted mortality.  
 
Laboratory Methods 
Biomerieux BacT/Alert 3DTM was used for blood culture incubation. Biomerieux API® 
Candida and Bruker MALDI-TOFTM mass spectrometry were used for Candida 
species identification. Sensititre YeastOneTM (TREK Diagnostic Systems) microbroth 
dilution was used to determine minimum inhibitory concentrations (MIC), and 
antifungal susceptibility was determined using Clinical Laboratory and Standards 
Institute (CLSI) guidelines.  
 
Data Analysis 
Data were stored and analysed using Microsoft Excel 2016. A two tailed T test 
assuming unequal variances was used to determine any statistical difference 
between means in C. albicans and C. glabrata groups where p=<0.05 was deemed 


















Distribution of Candida species (2004-2018) 
 
Between January 2004 and August 2018, 74 ICU patients developed candidemia. 
This represents an incidence rate of 17/1000 ICU admissions. Of the Candida 
species isolated, C. albicans was most prevalent accounting for 55% (n=41), with 
non-C.albicans accounting for 45% (n=33) (Table 1). Reduction in the incidence of 
C. albicans was observed from 2004-2018. In 2004, C. albicans accounted for 83% 
(n=5) of cases, while there was no case of C. albicans candidemia observed in the 
first eight months of 2018 (Table 1).  
 
Reduction in C. albicans correlated with increase in non-C. albicans species namely 
C. glabrata, C. parapsilosis and C. tropicalis. Between 2004-2018, C. glabrata 
accounted for 28% (n=21) of candidemia with C. parapsilosis and C. tropicalis each 
accounting for 14% (n=10). In 2004, C. glabrata was not isolated while in 2018 (up to 
August) C. glabrata was implicated in both recorded cases (Table 1). 
 
 
Determinants of C. albicans and C. glabrata candidemia patient groups 2004-2018 
 
Patient ages ranged from 22-88 years (mean 66 years) (Supplementary Material 
Table 1). Those infected with C. albicans (n=41) and C. glabrata (n=21) had a mean 
age of 65 years and 69 years, respectively (p=0.26). SOFA scores were found to be 
independent of causative Candida species, with a mean score of 9 across all groups 
(Supplementary Material Table 1) (p=0.52). Mean time from ICU admission to 
diagnosis of candidemia varied between those with C. albicans (7 days) and C. 
glabrata (4 days) (Supplementary Material Table 1) (p=0.26). The mean ICU LOS 
varied between those with C. albicans (21 days) and C. glabrata (18 days) (p=0.38). 
CVC lines were in situ for 80% of the candidemias. The overall 30-day mortality rate 
(2004-2018) for all candidemia was 39% (n=29), although varying between those 















Empirical treatment of suspected candidemia (2004-2018) 
 
Empirical treatment was administered to 78% (n=58) of patients with subsequent 
Candida positive blood culture. Azoles were administered in 59% (n=34) of cases 
with fluconazole accounting for 55% of all empirical treatments (Supplementary 
Material Table 2). Amphotericin B was given in 7% (n=5) of cases with its last 
recorded use in 2007. The first recorded use of an echinocandin (caspofungin) was 
2008 and has accounted overall for 33% (n=19) of empirical treatments 
(Supplementary Material Table 2). The most recent use of fluconazole as an 
empirical therapy was 2014.  
 
Anti-fungal agent susceptibility of Candida isolates (2004-2018) 
 
Candida antifungal susceptibility testing was performed using CLSI guidelines. From 
2004 to 2018, the antifungal susceptibility panel evolved significantly. Caspofungin 
was not included in the susceptibility panel prior to 2009 despite being used as an 
empirical therapy in 2008. 5-flucytosine was removed from the anti-fungal 
susceptibility panel in 2016. Susceptibility testing revealed all tested isolates were 
sensitive to caspofungin. Azole resistance was encountered frequently, with 37% of 
C. glabrata isolates being fluconazole resistant. This contrasts with just 2% of C. 
albicans being fluconazole-resistant. Amphotericin B resistance was not uncommon 
among C. glabrata isolates with 14% resistant in comparison to all tested C. albicans 
isolates being sensitive (Table 2). Mean and median susceptibility data are shown in 



















This study provided comprehensive insight regarding the changing epidemiology of 
candidemia in Ireland, which at 17/1000 ICU admissions was considerably more 
prevalent than the rate of 7.4/1000 ICU admissions reported previously in the UK [1] 
and for Northern Ireland [10]. 
Candida species isolated in Limerick over the 15-year study period comprised C. 
albicans, C. glabrata, C. tropicalis and C. parapsilosis and C. krusei. Several studies 
have demonstrated that these few Candida species account for the majority of 
candidemias, with our study providing further evidence [6].  C. albicans is the most 
frequently isolated species in invasive candidiasis globally [6] [7]. Similarly, in our 
study, C. albicans was the causative agent of most cases (55%), although lower than 
described in other major studies, including a 2014 study by ARTEMIS DISK that 
reported C. albicans accounting for 62% of invasive candidiasis [7]. More recent 
work has shown a reduction globally in C. albicans prevalence [6]. Although clear, 
the decline of C. albicans observed in this study has been gradual, with fluctuations, 
but correlated with increase in non-C. albicans isolates. Notably, C. albicans was not 
isolated in the first eight months of 2018 representing a marked decline. Conversely, 
other Candida species have elevated incidence, with C. glabrata accounting for the 
greatest proportion of non-C. albicans cases (28%). Should this trend persist, C. 
glabrata will likely replace C. albicans as the primary cause of invasive candidiasis in 
this setting.  
It is likely that patient characteristics influence candidemia. The SENTRY study 
highlighted C. albicans-induced candidemia in younger patients compared to C. 
glabrata; specifically, C. glabrata was isolated in 23% of those cases involving 
patients ≥65 in contrast to 3% of candidemias in those ≤15 [8]. The apparent 
association between age and Candida species was less clear in our study as there 
was no statistically significant age difference between C. albicans and C. glabrata 
patient groups.  
SOFA score is considered a useful predictor of mortality in ICU patients, with a score 
≤9 representing a predicted mortality of 33% while scoring ≥11 equates to predicted 
mortality of 95%. The mean SOFA score of 9 for all candidemia admissions to UHL 















candidemia (57%) were found to have a significantly higher mortality rate than those 
with a C. albicans candidemia (29%). Clearly, this is raising concerns in light of 
increasing C. glabrata prevalence. 
We found that empirical therapy was administered in the majority of candidemia 
cases (78%) and the choice of therapy informed by ESCMID guidelines. Overall, 
azoles accounted for 58% of treatments, of which fluconazole was most frequently 
prescribed (55%), albeit prior to 2014. Since then, empirical therapy has included 
caspofungin, with the initial recorded use in 2008. Indeed, all isolates tested in this 
study were caspofungin sensitive, thus providing assurance for its continued use as 
first line candidemia therapy. In stark relief, fluconazole susceptibility was less 
pertinent, with 37% of C. glabrata isolates resistant. This supports ESCMID 
recommendations reconsidering fluconazole as the drug of choice in an era of non-
C. albicans candidemia. With regard to potential resistance development, 
widespread fluconazole dosage has been known to increase C. glabrata prevalence 
secondary to selection pressure [9]. This may partly explain the rise of C. glabrata in 
this Irish setting given predominant use of fluconazole as an empirical therapy prior 
to 2012. Alarmingly, 14% of our C. glabrata isolates were amphotericin B resistant, 
whereas typical clinical isolates seldom exhibit amphotericin B resistance. It may be 
pertinent that since 2007, this hospital has consistently recorded less use of 
antifungals than the median for Irish tertiary hospitals. 
Our data reiterate the risk of candidemia for immunosuppressed patients, such as in 
ICU settings, with C. glabrata candidemia seen to have a particularly poor prognosis. 
All Candida isolates were susceptible to caspofungin, but C. glabrata was found to 
be significantly more resistant than C. albicans to fluconazole and amphotericin B. In 
the context of effective antifungal stewardship, our study suggests a need to evolve 
quickly from empirical and prophylactic use of antifungals that are currently effective, 
and towards adoption of rapid molecular diagnosis of candidemia and vigilance 
specific to the enhanced risks of drug-resistant C. glabrata. 
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Candida species encountered between January 2004 and August 2018 
Year C. albicans C. glabrata C. 
parapsilosis 
C. tropicalis Other* Total 
2004 5 0 1 0 0 6 
2005 2 2 0 0 0 4 
2006 4 0 0 1 0 5 
2007 3 1 0 0 0 4 
2008 7 3 0 2 0 12 
2009 3 0 2 0 0 5 
2010 2 3 0 0 0 5 
2011 1 0 1 0 0 2 
2012 2 3 0 1 0 6 
2013 4 3 1 0 0 8 
2014 2 1 1 0 1 5 
2015 2 2 0 0 0 4 
2016 0 2 0 0 0 2 
2017 4 0 0 0 1 5 
2018 0 1 0 0 0 1 
Total n=41(55%) n=21(28%) n=6(8%) n=4(6%) 2(3%) n=74(100%) 


































*Candida isolates were often not tested against the same panel of anti-fungal agents due to 














C. albicans C. glabrata 
5-Flucytosine n=66 n=37 n=19 
Sensitive n=63 (95%) n=36 (97%) n=19 (100%) 
Intermediate n=1 (2%) n=0 (0%) n=0 (0%) 
Resistant 
 
n=2 (3%) n=1 (3%) n=0 (0%) 
Amphotericin B n=72 n=41 n=21 
Sensitive n=67 (93%) n=41 (100%) n=18 (86%) 
Intermediate n=0 (0%) n=0 (0%) n=0 (0%) 
Resistant 
 
n=5 (7%) n=0 (0%) n=3 (14%) 
Fluconazole n=70 n=41 n=19 
Sensitive n=61 (87%) n=40 (98%) n=12 (65%) 
Intermediate n=0 (0%) n=0 (0%) n=0 (0%) 
Resistant 
 
n=9 (13%) n=1 (2%) n=7 (37%) 
Itraconazole n=71 n=41 n=19 
Sensitive n=63 (89%) n=39 (95%) n=14 (74%) 
Intermediate n=2 (3%) n=0 (0%) n=1 (5%) 
Resistant 
 
n=6 (8%) n=2 (5%) n=4 (21%) 
Caspofungin n=41 n=19 n=15 
Sensitive n=41 (100%) n=19 (100%) n=15 (100%) 
Intermediate n=0 (0%) n=0 (0%) n=0 (0%) 
Resistant n=0 (0%) n=0 (0%) n=0 (0%) 
